BNR Burning Rock Biotech Ltd

Nasdaq brbiotech.com


$ 13.29 $ 0.33 (2.54 %)    

Monday, 03-Nov-2025 12:52:14 EST
QQQ $ 632.28 $ -2.96 (-0.47 %)
DIA $ 473.80 $ -2.40 (-0.5 %)
SPY $ 683.49 $ -2.15 (-0.31 %)
TLT $ 89.58 $ -0.07 (-0.07 %)
GLD $ 368.37 $ -0.46 (-0.12 %)
$ 13.46
$ 13.18
$ 12.14 x 100
$ 13.64 x 100
$ 13.18 - $ 13.89
$ 2.18 - $ 13.68
24,100
na
1.45B
$ 1.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 burning-rock-biotech-q2-eps-010-up-from-140-yoy-sales-20737m-up-from-18650m-yoy

Burning Rock Biotech (NASDAQ:BNR) reported quarterly losses of $(0.10) per share. This is a 92.86 percent increase over losses ...

 burning-rock-biotech-q1-eps-020-up-from-160-yoy-sales-1834m-up-from-1740m-yoy

Burning Rock Biotech (NASDAQ:BNR) reported quarterly losses of $(0.20) per share. This is a 87.5 percent increase over losses o...

 burning-rock-biotech-q4-eps-011-up-from-022-yoy-sales-1730m-up-from-1705m-yoy

Burning Rock Biotech (NASDAQ:BNR) reported quarterly losses of $(0.11) per share. This is a 50 percent increase over losses of ...

 reported-earlier-burning-rock-and-dizal-secure-nmpa-approval-for-ngs-based-companion-diagnostic-for-lung-cancer-in-china

This marks the first co-developed NGS-based CDx for lung cancer approved by NMPA since the release of the CDx guideline in Chin...

 burning-rock-announces-the-resignation-of-mr-leo-li-as-a-director-and-as-the-cos-cfo-effective-september-27-2024-concurrently-ms-xiaozhi-hu-will-be-in-charge-of-financial-operations

Burning Rock Biotech Limited (NASDAQ:BNR) (the "Company" or "Burning Rock"), a company focused on the applicati...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION